Business
BNB Plus Provides BNB Treasury and Operational Updates
Company Acquires 3,349 Additional BNB Tokens LineaRx Subsidiary Expected to Narrow Losses and Approach Profitability in FY26Q1 Company Launches New Corporate
About this update from Bnb Plus Corp.
[{"type":"text","content":"\nCompany Acquires 3,349 Additional BNB Tokens\n\nLineaRx Subsidiary Expected to Narrow Losses and Approach Profitability in FY26Q1\n\nCompany Launches New Corporate Website and Branding\n\n NEW YORK--(BUSINESS WIRE)--\nBNB Plus Corp. (Nasdaq: BNBX) (“BNBX” or the “Company”), today provided a corporate update highlighting its recent strategic treasury growth, expected significant narrowing of losses at its LineaRx, Inc. (“LineaRx”) subsidiary, and the launch of a new corporate website and branding.\n\nSignificant Addition to BNB Treasury\n\nThe Company has opportunistically deployed an additional approximately $3 million to acquire additional BNB tokens at an average price of approximately $895 per token, further strengthening the Company’s yield focused BNB treasury strategy. The Company now holds a total of approximately 18,840 BNB through direct holdings and OBNB trust units.\n\nManagement continues to view BNB as a foundational strategic asset with meaningful long-term potential that remains broadly underappreciated. Consistent with that view, the Company intends to maintain a disciplined accumulation strategy aligned with its long-term value creation objectives. In parallel, the Company is advancing its efforts to integrate DeFi-based and native Binance yield opportunities directly into its operating and treasury framework, with the goal of generating durable yield, enhancing balance-sheet productivity, and driving sustained shareholder value.\n\nLineaRx Subsidiary Expected to Narrow Losses and Approach Profitability\n\nFollowing a comprehensive strategic restructuring and realignment of resources implemented earlier this year, LineaRx has significantly reduced its costs while maintaining its industry-leading capabilities in cell-free DNA production. Based on its reduced costs and an increase in customer shipments, the Company expects LineaRx to significantly narrow its losses for FY26Q1 (ending December 31, 2025) and approach profitability. Management views this milestone as a clear validation of its strategic realignment and believes it positions LineaRx to add accretive value beyond the Company’s BNB-based treasury strategy.\n\nLaunch of New Corporate Website and Rebranding\n\nThe Company recently launched its new corporate website at BNB.plus, together with an updated corporate logo. The refreshed branding and digital p...